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Extended-spectrum cephalosporins (ESC) are an
important drug class for treating severe Salmonella infec-
tions. We screened the human collection from the National
Antimicrobial Resistance Monitoring System 2000 for ESC
resistance mechanisms. Of non-Typhi Salmonella tested,
3.2% (44/1,378) contained blaCMY genes. Novel findings
included  blaCMY-positive  Escherichia coli O157:H7 and a
blaSHV-positive  Salmonella isolate. CMY-positive isolates
showed a ceftriaxone MIC >2 µg/mL.
E
xtended-spectrum cephalosporins (ESC) are important
for treating persons with severe Salmonella infections
(1). This drug class is particularly important for pediatric
therapy because fluoroquinolones are not approved for use
in children. In 2000, 25% (8,153/32,022) of laboratory-
confirmed Salmonella cases reported to the Centers for
Disease Control and Prevention (CDC) occurred in chil-
dren <5 years of age (2).
The National Antimicrobial Resistance Monitoring
System (NARMS) for Enteric Bacteria began monitoring
for resistance to cephalosporins and other drugs among
human-derived Salmonella and Escherichia coli O157 iso-
lates in 1996. Shigella was added to the surveillance in
1999. From 1996 to 1998, 15 (0.4%) of 4,093 non-typhi
Salmonella isolates tested by NARMS were resistant to
ESC, and none of the 675 E. coli O157 isolates tested were
ESC resistant (3). Thirteen (87%) of 15 ESC-resistant
Salmonella isolates exhibited a blaCMY-2-mediated mecha-
nism of resistance (3,4), including 11 serotype
Typhimurium, 1 Thompson, and 1 Newport. One S. Cubana
isolate exhibited a blaKPC-2 carbapenemase (5), and the
remaining S. Typhimurium isolate exhibited a yet-unchar-
acterized extended-spectrum β-lactamase (3). To determine
the dynamics and mechanisms of cephalosporin resistance
among species and serotypes, we examined the 2000
NARMS collection and determined mechanisms of ESC
resistance in isolates exhibiting elevated cephalosporin
MICs. 
The Study
As NARMS participants, 17 state and local public
health laboratories representing 40% of the US population
submitted every tenth non-Typhi Salmonella isolate, every
tenth Shigella isolate, and every fifth E. coli O157 isolate
received in 2000 to CDC for antimicrobial susceptibility
testing. Identification and serotyping were conducted at
submitting laboratories. The MIC was determined for 17
antimicrobial agents at CDC by using partial range broth
microdilution (Sensititre, Westlake, OH, USA). Isolates
were chosen for further study based on the following MIC
criteria: cefoxitin (>16 µg/mL), ceftiofur (>4 µg/mL), or
ceftriaxone (>16 µg/mL). 
Isoelectric Focusing (IEF) for β β-Lactamases
β-Lactamase content was determined for all isolates
that met the MIC criteria for further study. The IEF meth-
ods of Rasheed et al. (6) were used with modification.
Crude cellular protein extracts were prepared by pelleting
3-hour trypticase soy broth cultures (grown at 37°C with
shaking at 300 rpm), resuspending in 0.2% sodium acetate
at 5% of original culture volume, and freeze-thawing 4
times in a dry ice/ethanol bath and a 37°C water bath.
Preparations were then diluted twofold with distilled water
and placed on ice for 30 min with occasional swirling. The
supernatant was collected after centrifuging for 30 min at
maximum relative centrifugal force (14,000 rpm) in a
Beckman 5417R microcentrifuge (Palo Alto, CA, USA).
Three- to 5-µL aliquots of each preparation were resolved
by focusing for 1.5 h on an Ampholine PAGplate polyacry-
lamide gel, pH range 3.5–9.5 (APBiotech, Piscataway, NJ,
USA), according to manufacturer’s instructions. Gels were
stained by overlaying with a 500 µg/mL solution of nitro-
cefin (Becton Dickinson, Franklin Lakes, NJ, USA).
Isoelectric points were estimated by comparison with the
following standard β-lactamases: TEM-12 (pI 5.25), SHV-
3 (pI 7.0) and MIR-1 (pI 8.4).
Polymerase Chain Reaction (PCR) 
for β β-Lactamase Genes
For isolates that were IEF-positive for a β-lactamase
with a pI >8.4, amplification of blaCMY genes was attempt-
ed. Internal primers were used to amplify a 369-bp portion
of blaCMY genes from crude colony lysates. The forward
primer anneals to nucleotide (nt) 271–289 of the 1,146-nt
blaCMY-2 sequence from Klebsiella pneumoniae (NCBI
accession no. X91840) and has a sequence of 5′-GGCGT-
GTTGGGCGGCGATG-3′. The reverse primer anneals to
nt 621-639 of blaCMY-2 and has a sequence of 5′-CAGCG-
GAACCGTAATCCAG-3′. APBiotech Ready-to-Go
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µL reactions, which were run in an MJResearch thermocy-
cler (Waltham, MA, USA) under the following conditions:
1 cycle of 94°C for 5 min followed by 25 cycles of: 94°C
for 30 s, 59°C for 1 min, 72°C for 1 min. Amplicons were
resolved by electrophoresis in 1% agarose gels. For iso-
lates exhibiting a β-lactamase with a pI = 8.0, blaSHV genes
were amplified using primers 4 and 5 from Rasheed et al.
(7) with Perkin-Elmer Amplitaq Gold 2X Master Mix
(Boston, MA, USA). 
Conclusions
In 2000, 2,152 non-Typhi Salmonella, Shigella, and E.
coli O157 isolates were received and tested. Of these, 57
(2.6%) met the MIC criteria for additional testing to deter-
mine mechanisms of extended-spectrum cephalosporin
resistance: 46 non-Typhi Salmonella isolates, 7 Shigella
isolates (all S. sonnei), and 4 E. coli O157:H7 (Table).
blaCMY genes were identified in 44 (96%) of the 46
Salmonella isolates. One S. Nienstedten isolate produced a
blaSHV enzyme with a pI of 8.0. One S. Muenchen isolate
with a cefoxitin MIC = 16 µg/mL yielded no β-lactamases
by IEF. This isolate exhibited very low MIC of ceftriaxone
and ceftiofur (<0.25 and <0.5 µg/mL, respectively).
The 7 S.  sonnei isolates included in the study met only
the cefoxitin MIC criterion (>16 µg/mL). All 7 showed a
ceftiofur MIC 1.0 µg/mL or less, and a ceftriaxone MIC
<0.25 µg/mL. Six of these were also resistant to ampicillin,
amoxicillin-clavulanate, and cephalothin. Each isolate was
IEF-positive for a β-lactamase enzyme with a pI>8.4, but
was polymerase chain reaction–negative for a blaCMY
gene. We suspect the resistance is related to overproduc-
tion of chromosomal ampC genes known to be present in
Shigella species (8); however, porin deficiency (9) and
penicillin-binding protein changes (10) are worth explo-
ration as well. Efflux mechanisms (11,12) are possible, but
multidrug-resistance pumps might be less likely since
none of the 7 isolates were resistant to chloramphenicol,
nalidixic acid, or ciprofloxacin, and only 4 were resistant
to tetracycline.
Eight isolates (5 Salmonella and 3 S. sonnei) produced
putative TEM enzymes in addition to an enzyme with a
pI>8.4. The pI in each case was 5.3 or 5.4. Plasmidborne
blaTEM-1  enzymes have been identified in several
Salmonella serotypes (13). 
Twenty-seven (61%) of 44 blaCMY-containing
Salmonella in 2000 were serotype Newport. This finding
coincides with emergence of a multidrug-resistant strain of
S. Newport called MDRAmpC (14). MDRAmpC
increased from 1% (1/77) of S. Newport isolates tested by
NARMS in 1998 to 22% (27/124) in 2000 (15). In addi-
tion,  blaCMY genes were found in 5 other Salmonella
serotypes (Typhimurium, Heidelberg, Agona, Infantis, and
Reading) in 2000. This contrasts with 1996–1998, when
blaCMY was found in 3 serotypes (Newport, Typhimurium,
and Thompson), which indicated that these genes or the
mobile elements that house them have been disseminated.
Furthermore, blaCMY genes were identified in each of the 4
E. coli O157:H7 isolates that met the MIC criteria in 2000.
To our knowledge, this is the first report of blaCMY in this
E. coli serotype. 
All 48 blaCMY-positive isolates (44 Salmonella and 4 E.
coli O157:H7) exhibited a ceftiofur MIC >8 µg/mL; how-
ever, their ceftriaxone MIC ranged from 2 to 32 µg/mL.
Since the Clinical and Laboratory Standards Institute (for-
merly National Committee for Clinical Laboratory
Standards) breakpoint for ceftriaxone resistance is 64
µg/mL, none of these isolates were interpreted as ceftriax-
one-resistant, and only 48% (23/48) were intermediate (16
or 32 µg/mL). In contrast, all 48 CMY-producing isolates
showed a cefoxitin MIC >16 µg/mL (intermediate or
resistant according to CLSI guidelines). 
NARMS sampling in 2000 showed that blaCMY genes
continue to be the major mechanism of extended-spectrum
cephalosporin resistance among non-Typhi Salmonella;
other mechanisms of ESC are rare. The increasing diversi-
ty of blaCMY-positive Salmonella serotypes and the discov-
ery of blaCMY genes in E. coli  O157:H7 highlight the
mobility of these mechanisms. This finding is not unex-
pected since these genes have been shown to be present on
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tion (4). Since S. Newport MDRAmpC and E. coli
O157:H7 have been associated with bovine reservoirs, we
hypothesize that blaCMY genes may be circulating among
cattle. This remains to be proven and warrants more inten-
sive study of blaCMY prevalence and movement in bovine
production settings. Further research is also necessary to
determine factors that contribute to dissemination of the
mobile elements carrying these genes and selection of
blaCMY-positive strains such as S. Newport MDRAmpC.
Notably, isolates exhibiting this extended-spectrum
cephalosporinase may show a ceftriaxone MIC as low as 2
µg/mL, but MIC to ceftiofur and cefoxitin fall more reli-
ably in the intermediate or resistant range. For this reason,
we currently performed subsequent β-lactamase analysis
on any isolate exhibiting a ceftriaxone or ceftiofur MIC >2
µg/mL. 
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